These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18047674)

  • 1. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring.
    Wang XD; Reeves K; Luo FR; Xu LA; Lee F; Clark E; Huang F
    Genome Biol; 2007; 8(11):R255. PubMed ID: 18047674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.
    Huang F; Reeves K; Han X; Fairchild C; Platero S; Wong TW; Lee F; Shaw P; Clark E
    Cancer Res; 2007 Mar; 67(5):2226-38. PubMed ID: 17332353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy.
    Moulder S; Yan K; Huang F; Hess KR; Liedtke C; Lin F; Hatzis C; Hortobagyi GN; Symmans WF; Pusztai L
    Mol Cancer Ther; 2010 May; 9(5):1120-7. PubMed ID: 20423993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
    Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
    Yu EY; Wilding G; Posadas E; Gross M; Culine S; Massard C; Morris MJ; Hudes G; Calabrò F; Cheng S; Trudel GC; Paliwal P; Sternberg CN
    Clin Cancer Res; 2009 Dec; 15(23):7421-8. PubMed ID: 19920114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.
    Yu EY; Duan F; Muzi M; Deng X; Chin BB; Alumkal JJ; Taplin ME; Taub JM; Herman B; Higano CS; Doot RK; Hartfeil D; Febbo PG; Mankoff DA
    J Nucl Med; 2015 Mar; 56(3):354-60. PubMed ID: 25635138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
    Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
    Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib: BMS 354825.
    Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
    Nam S; Williams A; Vultur A; List A; Bhalla K; Smith D; Lee FY; Jove R
    Mol Cancer Ther; 2007 Apr; 6(4):1400-5. PubMed ID: 17431118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
    Herrmann MD; Lennerz JK; Bullinger L; Bartholomae S; Holzmann K; Westhoff MA; Corbacioglu S; Debatin KM
    Exp Hematol; 2014 Feb; 42(2):90-100. PubMed ID: 24211243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
    Hiwase DK; Saunders V; Hewett D; Frede A; Zrim S; Dang P; Eadie L; To LB; Melo J; Kumar S; Hughes TP; White DL
    Clin Cancer Res; 2008 Jun; 14(12):3881-8. PubMed ID: 18559609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
    Jabbour E; Cortes J; Kantarjian H
    Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
    Taylor MJ; Scuffham PA
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial testing of dasatinib by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Houghton PJ; Morton CL; Lock RB; Tajbakhsh M; Reynolds CP; Maris JM; Keir ST; Billups CA; Smith MA
    Pediatr Blood Cancer; 2008 Jun; 50(6):1198-206. PubMed ID: 17914733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
    Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H
    J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
    Hochhaus A
    Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias.
    Santos FP; Cortes J
    Expert Opin Pharmacother; 2012 Nov; 13(16):2381-95. PubMed ID: 22992064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity.
    Teng Y; Cai Y; Pi W; Gao L; Shay C
    J Hematol Oncol; 2017 Jun; 10(1):118. PubMed ID: 28606127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.
    Verstovsek S; Tefferi A; Cortes J; O'Brien S; Garcia-Manero G; Pardanani A; Akin C; Faderl S; Manshouri T; Thomas D; Kantarjian H
    Clin Cancer Res; 2008 Jun; 14(12):3906-15. PubMed ID: 18559612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.